肌层浸润性膀胱癌的放射治疗:三级医疗中心的当代结局
这项多中心回顾性研究纳入2002至2018年864例接受根治性放疗的非转移性肌层浸润性膀胱癌患者,分析完全缓解和生存的预测因素。592例(78%)达完全缓解,5年癌症特异性生存率63%、总生存率49%。cT3-4期和肾积水与完全缓解率降低相关;新辅助化疗和全盆腔放疗与癌症特异性生存及总生存改善独立相关。
要点
- 864例接受根治性放疗的肌层浸润性膀胱癌患者中,592例(78%)达完全缓解。
- cT3-4期(OR 0.43)和肾积水(OR 0.50)与完全缓解率降低显著相关。
- 新辅助化疗(HR 0.66)和全盆腔放疗(HR 0.66)与癌症特异性生存改善独立相关。
核心结论
- 根治性放疗使多数选择保留膀胱的肌层浸润性膀胱癌患者达完全缓解。
- 新辅助化疗和全盆腔放疗的获益需前瞻性试验验证。
研究设计与样本
- 多中心回顾性研究,纳入2002年至2018年864例接受根治性放疗的非转移性肌层浸润性膀胱癌患者。
主要发现
- 患者中位年龄77岁,中位随访34个月;疾病分期cT2者675例(78%),cN0者766例(89%)。
- 147例(17%)接受新辅助化疗,542例(63%)接受同步化疗;592例(78%)达完全缓解。
- 5年癌症特异性生存率为63%,总生存率为49%。
- 与癌症特异性生存独立相关的因素:较高cT分期(HR 1.93,95%CI 1.46-2.56;p<0.001)、原位癌(HR 2.10,95%CI 1.25-3.53;p=0.005)、肾积水(HR 2.36,95%CI 1.79-3.10;p<0.001)、新辅助化疗(HR 0.66,95%CI 0.46-0.95;p=0.025)、全盆腔放疗(HR 0.66,95%CI 0.51-0.86;p=0.002)。
临床怎么用
- 作者认为,新辅助化疗和全盆腔放疗的获益需前瞻性试验验证。
局限性
- 研究受不同治疗方案异质性的限制。
- 新辅助化疗和全盆腔放疗的获益需前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiation therapy (RT) is an alternative to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). OBJECTIVE: To analyze predictors of complete response (CR) and survival after RT for MIBC. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective study of 864 patients with nonmetastatic MIBC who underwent curative-intent RT from 2002 to 2018. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Regression models were used to explore prognostic factors associated with CR, cancer-specific survival (CSS), and overall survival (OS). RESULTS AND LIMITATIONS: The median patient age was 77 yr and median follow-up was 34 mo. Disease stage was cT2 in 675 patients (78%) and cN0 in 766 (89%). Neoadjuvant chemotherapy (NAC) was given to 147 patients (17%) and concurrent chemotherapy to 542 (63%). A CR was experienced by 592 patients (78%). cT3-4 stage (odds ratio [OR] 0.43, 95% confidence interval [CI] 0.29-0.63; p < 0.001) and hydronephrosis (OR 0.50, 95% CI 034-0.74; p = 0.001) were significantly associated with lower CR. The 5-yr survival rates were 63% for CSS and 49% for OS. Higher cT stage (HR 1.93, 95% CI 1.46-2.56; p < 0.001), carcinoma in situ (HR 2.10, 95% CI 1.25-3.53; p = 0.005), hydronephrosis (HR 2.36, 95% CI 1.79-3.10; p < 0.001), NAC use (HR 0.66, 95% CI 0.46-0.95; p = 0.025), and whole-pelvis RT (HR 0.66, 95% CI 0.51-0.86; p = 0.002) were independently associated with CSS; advanced age (HR 1.03, 95% CI 1.01-1.05; p = 0.001), worse performance status (HR 1.73, 95% CI 1.34-2.22; p < 0.001), hydronephrosis (HR 1.50, 95% CI 1.17-1.91; p = 0.001), NAC use (HR 0.69, 95% CI 0.49-0.97; p = 0.033), whole-pelvis RT (HR 0.64, 95% CI 0.51-0.80; p < 0.001), and being surgically unfit (HR 1.42, 95% CI 1.12-1.80; p = 0.004) were associated with OS. The study is limited by the heterogeneity of different treatment protocols. CONCLUSIONS: RT for MIBC yields a CR in most patients who elect for curative-intent bladder preservation. The benefit of NAC and whole-pelvis RT require prospective trial validation. PATIENT SUMMARY: We investigated outcomes for patients with muscle-invasive bladder cancer treated with curative-intent radiation therapy as an alternative to surgical removal of the bladder. The benefit of chemotherapy before radiotherapy and whole-pelvis radiation (bladder plus the pelvis lymph nodes) needs further study.
引用
- Kool R, Marcq G, Breau RH, et al. Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers. Eur Urol Oncol. 2023. PMID: 37005214. doi:10.1016/j.euo.2023.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。